Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis

Wongvibulsin, Shannon; Pahalyants, Vartan; Kalinich, Mark; Murphy, William S.; Yu, Kun; Wang, Feicheng; Chen, Shuo; Reynolds, Kerry L.; Kwatra, Shawn G.; Semenov, Yevgeniy R.

doi:10.1016/j.jaad.2021.03.094

Cited by 73 publications

(85 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though our patient received nivolumab for more than 2 years, he never developed an episode of irHepatitis again. However, the further course of treatment was complicated by lichen ruber, a known but rather rare dermatological adverse event during ICI treatment, [10] that occurred approximately 1 year after nivolumab initiation.…”

Section: Discussionmentioning

confidence: 99%

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Scheiner

Pinter

2021

memo

View full text Add to dashboard Cite

SummaryWe present a case of a male patient with advanced hepatocellular carcinoma who developed hepatic and dermatological immune-related adverse events during treatment with the immune checkpoint inhibitor nivolumab. We discuss relevant aspects regarding the management of immune-related hepatic adverse events, including the incidence and onset of the event, the requirement for immune-modulating medication, resuming of immunotherapy, and the association between the occurrence of immune-related adverse events and the outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Scheiner

Pinter

2021

memo

View full text Add to dashboard Cite

show abstract

“…2 irAE affect more than half of the treated patients and can affect multiple organ systems, with dermatologic irAE being the most frequently reported, occurring in 25.1% of patients. 3 Therefore, it becomes increasingly important for both dermatology and non-dermatology clinicians to be able to recognise and manage cutaneous irAE appropriately as ICI become more commonly utilised. Most commonly reported cutaneous irAE include maculopapular eruption and pruritus.…”

mentioning

confidence: 99%

“…Most commonly reported cutaneous irAE include maculopapular eruption and pruritus. 3 To our knowledge, there are 15 cases of pembrolizumab-induced EM reported to date. [3][4][5] In contrast to lichenoid drug eruption, which has also been reported as a cutaneous irAE, EM usually presents with circular, often targetoid, papules that start on the palms and soles and has somewhat different histopathological findings, usually with more vacuolar than lichenoid interface dermatitis.…”

mentioning

confidence: 99%

“…3 To our knowledge, there are 15 cases of pembrolizumab-induced EM reported to date. [3][4][5] In contrast to lichenoid drug eruption, which has also been reported as a cutaneous irAE, EM usually presents with circular, often targetoid, papules that start on the palms and soles and has somewhat different histopathological findings, usually with more vacuolar than lichenoid interface dermatitis. While systemic immunosuppression should be avoided in an effort to retain anti-tumour immunity, it is sometimes necessary when managing more severe cases of cutaneous irAE.…”

mentioning

confidence: 99%

“…6 While high-grade cutaneous irAE are reported to occur in only 5% of patients receiving ICI therapy, patients should be followed up closely to monitor for potential cutaneous irAE, and urgent referral to dermatology should be made when the diagnosis is unclear. 3…”

mentioning

confidence: 99%

See 2 more Smart Citations

Pembrolizumab‐induced erythema multiforme requiring systemic immunosuppression

Shih

Sharaf

2021

Internal Medicine Journal

View full text Add to dashboard Cite

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

et al. 2022

View full text Add to dashboard Cite

IMPORTANCE Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our knowledge, little is known about the predictive value of these cutaneous eruptions and their subtypes regarding cancer survival.OBJECTIVE To determine the association of developing cirAEs following treatment with anti-programmed cell death 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) therapy with patient survival. DESIGN, SETTING, AND PARTICIPANTSThis retrospective cohort study used data from the TriNetX Diamond Network, a database of health records and claims data from more than 200 million US and European patients, to conduct a population-level cohort analysis. The study included 7008 eligible patients who developed cirAEs after treatment with anti-PD-1 or anti-PD-L1 therapy for malignant neoplasms of digestive organs, bronchus or lung, melanoma of skin, and urinary tract who were identified through the TriNetX Diamond Network along with 7008 matched controls.EXPOSURES Development of cirAEs within 6 months following anti-PD-1 or anti-PD-L1 therapy. MAIN OUTCOMES AND MEASURESA 6-month analysis using a Cox proportional hazards model was performed to determine the association of cirAEs with overall survival after adjusting for demographic characteristics, cancer type, and cancer stage. RESULTS A total of 7008 patients (3036 women [43.3%]; mean [SD] age, 68.2 [11.2] years) were matched to 7008 (3044 women [43.4%]; mean [SD] age, 68.3 [11.1] years) controls.

show abstract

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis

Cited by 73 publications

References 46 publications

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Pembrolizumab‐induced erythema multiforme requiring systemic immunosuppression

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

Contact Info

Product

Resources

About